A. Harstrick

10.7k total citations · 1 hit paper
128 papers, 8.2k citations indexed

About

A. Harstrick is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Harstrick has authored 128 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 40 papers in Molecular Biology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Harstrick's work include Colorectal Cancer Treatments and Studies (33 papers), Cancer Treatment and Pharmacology (30 papers) and Testicular diseases and treatments (29 papers). A. Harstrick is often cited by papers focused on Colorectal Cancer Treatments and Studies (33 papers), Cancer Treatment and Pharmacology (30 papers) and Testicular diseases and treatments (29 papers). A. Harstrick collaborates with scholars based in Germany, United States and United Kingdom. A. Harstrick's co-authors include Yves Humblet, Harry Bleiberg, David Cunningham, M. Mueser, Armando Santoro, David Khayat, Chris Verslype, Eric Van Cutsem, Ian Chau and Salvatore Siena and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

A. Harstrick

126 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 3.9k citations A. Harstrick et al. profile →

Peers

Countries citing papers authored by A. Harstrick

Since Specialization

Citations

This map shows the geographic impact of A. Harstrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Harstrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Harstrick more than expected).

Fields of papers citing papers by A. Harstrick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Harstrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Harstrick. The network helps show where A. Harstrick may publish in the future.

Co-authorship network of co-authors of A. Harstrick

This figure shows the co-authorship network connecting the top 25 collaborators of A. Harstrick. A scholar is included among the top collaborators of A. Harstrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Harstrick. A. Harstrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study 2024 ·Blood ·Pau Montesinos, Montserrat Arnán, Stéphane de Botton, María Calbacho, (unknown), Pierre Bories, Belén Ansoleaga, Thomas Hueso, Naval Daver, Lydia Wunderle, A. Harstrick, (unknown), (unknown), (unknown), Tania Witte, Eugene L. Saenger, Christian Récher	3
2	Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors 2016 ·Annals of Oncology ·Mark R. Middleton, (unknown), Sanjeev Kumar, (unknown), Jordi Rodón, Karin H. Herbschleb, J. A. Steiner, Christof Zitt, Daniel Feurstein, Sabrina Schreiner, (unknown), Keith M. Dawson, (unknown), (unknown), Michael T. Stumpp, A. Harstrick, Richard D. Baird, Aurelius Omlin	4
3	Keimzelltumoren des Hodens: Epidemiologische und ätiologische Aspekte 2008 ·DMW - Deutsche Medizinische Wochenschrift ·Carsten Bokemeyer, A. Harstrick, (unknown), Hans‐Joachim Schmoll, H. Poliwoda	2
4	Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC 2004 ·Radiotherapy and Oncology ·Mechthild Krause, (unknown), Cordula Petersen, N. Pimentel, Franziska Hessel, A. Harstrick, Michaël Baumann	55
5	Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study† 2003 ·Annals of Oncology ·Mitra Tewes, N. Schleucher, W. Achterrath, Hans‐Joachim Wilke, S. Frings, S. Seeber, A. Harstrick, Youcef M. Rustum, U. Vanhoefer	46
6	Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells 1999 ·Journal of Clinical Apheresis ·Peter Bojko, N. Nowak, (unknown), Michael Flaßhove, A. Harstrick, S. Seeber	2
7	Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors 1998 ·Cancer Chemotherapy and Pharmacology ·Ralf A. Hilger, A. Harstrick, Wilfried Eberhardt, C. Oberhoff, (unknown), Joachim Baumgart, S. Seeber, M. E. Scheulen	55
8	Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. 1997 ·PubMed ·U. Vanhoefer, Wieland Voigt, Ralf A. Hilger, Mingzhu Yin, A. Harstrick, S. Seeber, Y M Rustum	5
9	Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) 1997 ·Annals of Oncology ·U. Vanhoefer, Shousong Cao, A. Harstrick, S. Seeber, Youcef M. Rustum	63
10	Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro 1997 ·Anti-Cancer Drugs ·Michael Ståhl, Sabine Kasimir‐Bauer, A. Harstrick	13
11	A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer 1996 ·Oncology Research and Treatment ·A. Harstrick, Hans‐Joachim Wilke, Wilfried Eberhardt, U. Klaassen, Dirk Strumberg, Michael Korn, M. E. Scheulen, Joachim Baumgart, S. Seeber	20
12	Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer 1996 ·Annals of Oncology ·Hans‐Joachim Wilke, U. Klaassen, W. Achterrath, (unknown), U. Vanhoefer, (unknown), A. Harstrick, Michael Ståhl, Wilfried Eberhardt, R. Becher, S. Seeber	14
13	Treatment of Adult Soft-Tissue Sarcomas with Dose-Intensified Chemotherapy and Haematopoietic Growth Factors 1994 ·Oncology Research and Treatment ·Carsten Bokemeyer, A. Harstrick, Hans‐Joachim Schmoll	4
14	Phase II Study with Folinic Acid, Etoposide, 5-Fluorouracil and Cisplatin (FLEP) for Advanced Gastric Cancer 1994 ·Oncology Research and Treatment ·H. Wilke, P. Preusser, M. Stahl, (unknown), U. Fink, W. Achterrath, (unknown), J. Meyer, A. Harstrick, Hans‐Joachim Schmoll, S. Seeber	0
15	Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer 1993 ·Cancer ·(unknown), (unknown), A. Harstrick, Carsten Bokemeyer, Andreas Mügge, M. Stahl, H. Wilke, H. Poliwoda, Wolfgang Hiddemann, (unknown), (unknown), (unknown), Hans‐Joachim Schmoll	89
16	Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines 1993 ·European Journal of Cancer ·A. Harstrick, Hans‐Joachim Schmoll, (unknown), (unknown), Youcef M. Rustum	26
17	A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours 1993 ·European Journal of Cancer ·C. Bokemeyer, Hans‐Joachim Schmoll, A. Harstrick, H. J. Illiger, Bernd Metzner, U. Räth, (unknown), C. Clemm, Wolfgang E. Berdel, W. Siegert, U. Rüther, Helmut Ostermann, Michael Kneba, J. Hartlapp, (unknown), H. Poliwoda	21
18	Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas 1992 ·Annals of Oncology ·Carsten Bokemeyer, A. Harstrick, Hans‐Joachim Schmoll, (unknown), Patrick Schöffski, H. Poliwoda	7
19	Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus 1992 ·Cancer Chemotherapy and Pharmacology ·A. Harstrick, Carsten Bokemeyer, P. Preusser, (unknown), Hans‐Joachim Meyer, Michael Ståhl, H. Knipp, Hans‐Joachim Schmoll, H. Wilke	16
20	Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk 1991 ·Oncology Research and Treatment ·M. Stahl, H. Wilke, P. Preusser, U. Fink, W. Achterrath, C. Schöber, (unknown), A. Harstrick, H. J. Meyer, J. Meyer, Luigi Lenaz, Hans‐Joachim Schmoll	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact